COVID-19 in the Immunocompromised Host, Including People with Human Immunodeficiency Virus - 28/05/22
, Aruna K. Subramanian, MD a, Adrienne E. Shapiro, MD, PhD b, cRésumé |
This review describes the incidence, epidemiology, and risk factors for mortality of COVID-19 in immunocompromised patients, including persons with human immunodeficiency virus. It describes various preventive measures, including vaccines and their effectiveness and the role of monoclonal antibodies for pre-exposure prophylaxis. It also reviews the different treatment options for immunocompromised individuals, including antivirals, monoclonal antibodies, and immunomodulators. Lastly, it describes the impact of COVID-19 on transplantation and continuity care of this population.
Le texte complet de cet article est disponible en PDF.Keywords : HIV, Immunocompromise, CD4, COVID-19, SARS-CoV-2, Solid organ transplant, Immunosuppression, Hematopoietic stem cell transplant
Plan
Vol 36 - N° 2
P. 397-421 - juin 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
